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paper provides a largely UK-perspective on treating ESKF without RRT. Emphasis is on the need for highquality evidence to inform treatment decisions. Complexities of defining, delivering and improving treatment of ESKF without dialysis care are explored. Quantitative and qualitative evidence are summarized and the relationship with palliative and terminal care examined. A framework is suggested for classifying management of ESKF and recommendations made to improve delivery of nondialysis care in the future. For patients with a poor prognosis, such treatment may not result in significantly different survival or quality of life when compared with dialysis. There is a key need to generate the best possible evidence of person-centered health outcomes associated with the various treatment options for ESKF and to present this to patients in a balanced, personalized way that allows them to make the treatment decision most appropriate for them.
Renal replacement therapy (RRT) using dialysis has been available for the treatment of end-stage kidney failure (ESKF) from the 1960s. Early technology and availability meant it was offered only to those with the best prognosis. Infamously, this led to the development of committees responsible for directing limited capacity toward those felt most 'eligible' (1) . RRT remains an expensive therapy largely unavailable to the populations of lower income countries (2, 3) . In higher income countries, successive health policy changes have seen progressive service expansion, and capacity no longer restricts dialysis provision. Improvement in outcomes from long-term dialysis allows patients with ESKF to live longer (4) . Despite a plateauing of RRT incidence in many countries, the prevalent population receiving dialysis continues to expand (5) . Compounded by the limited supply of transplant organs, the population with ESKF has shifted from largely working-age people with single organ disease to one increasingly comprising older, more comorbid individuals, predominantly receiving in-center hemodialysis (6) . With the United Kingdom general population aged over 65 predicted to increase by 60%, from 10.3 to 16.9 million by 2035 this trend seems set to continue (7) .
As people live longer and die with chronic, noncommunicable disease, cultural attitudes toward illness, treatment and death have changed (8) . Illness and dying are perceived as preventable, even in an individual's older and last years. In the United Kingdom, almost half of adults die in a hospital bed (9) and about one in five Americans die during a hospitalization including intensive care (10) . Patients approaching the end of life are frequently in receipt of polypharmacy (11) . Revolutionary advances in medicine have been replaced by gradual refinement of practice and development of increasingly expensive, higher technology treatments with slighter, incremental benefits to the individual. In parallel, there has been a practice shift away from paternalistic medicine toward increasingly holistic and patient-centered care. Shared decision-making empowers individuals and their carers to make choices about what care they want based on honest, open disclosure of the known benefits and risks of proposed treatment options (12) . The model of 'cumulative complexity' recognizes a requirement for individuals to cope with demands of illness and treatment, and that incapacity to cope with these demands can lead to further negative health outcomes (13) . So called 'minimally disruptive medicine' advocates a pragmatic approach to therapeutic recommendations in an effort to minimize treatment burden on patients and their carers, especially those with major comorbidity or approaching the end of life (14) .
Preparation for RRT involves planning for incenter hemodialysis for most older comorbid patients with advanced chronic kidney disease (CKD) and guidelines promote education and vascular access well in advance of ESKF (15) (16) (17) . The benefits of this approach are available only to those who survive to start RRT, whereas every patient is exposed to the burdens and associated risk of harm of preparing for dialysis. Some individuals elect for the symptoms and complications of their kidney disease to be managed without RRT. Terminology for this approach includes 'comprehensive conservative care' (CCC-used in this paper) (18) , 'nondialysis care' and 'conservative kidney management' (19, 20) . The comparative effectiveness of dialysis and CCC has been studied in countries which have formally introduced such pathways and is discussed in more detail below.
Historically, the UK RRT program has had lower uptake than many other countries with comparable populations, although rates have increased (21) . It is not easy to disentangle the role of rationing (implicit or explicit) in this, as compared with careful and appropriate use of treatment. Nevertheless, CCC is more accepted in the United Kingdom than in many other developed countries, affording a key perspective from which to examine the evidence base for its appropriate and effective development. In this paper, the complexities surrounding definition and identification of ESKF are examined. Pathways of CKD care are illustrated and a treatment classification advanced. Quantitative and qualitative evidence of outcomes and experiences of CCC and dialysis are summarized. Approaches to the development of higher quality evidence to support clinicians and patients in making betterinformed decisions about how to plan for ESKF are proposed.
Incidence and Prevalence of ESKF
Robust, population-based data to describe ESKF epidemiology are unavailable ( Fig. 1 ). RRT registries only systematically collect individual patient outcomes and describe the natural history of RRTtreated ESKF. RRT receipt is influenced by levels of detection of advanced CKD, referral and acceptance on to RRT. Internationally, RRT treatment has been increasing steadily over the last few decades, although rates in higher income countries have stabilized more recently (5) . While this increase is substantially due to population ageing, rising prevalence of diabetes and decline in competing mortality risk from cardiovascular disease, it also reflects expansion in dialysis services and changing referral and acceptance rates, highlighting the inadequacy of studying ESKF epidemiology using RRT receipt. Hospitalization data are an invalid measure of ESKF incidence or prevalence because they relate only to known treated inpatient cases and lack clarity due to insufficiencies in International Classification of Diseases coding. Beyond reach of routinely captured data are those with undiagnosed ESKF who have never had blood tests. Mortality data are unreliable because of under-ascertainment of renal disease on death certificates (22) . Cohort studies suggest the incidence of CKD has been relatively stable in comparison with growth in RRT-treated ESKF (23), but CKD registries are not widespread.
RRT treatment in the United Kingdom has been rising fastest among those aged over 75 years, who now account for almost a quarter of new dialysis patients (21) . Comorbidity is prevalent and increases with age (6). Of patients aged over 65 commencing dialysis, 82% receive hemodialysis (21) and transplantation is not an option for most, especially once aged over 75 (24) . Fifty-five percent of 65-74 year olds and 40% of those aged 75 or over survive 3 years. However, 30% of over-85 year olds die within 1 year of commencing dialysis (4). Early mortality is probably underestimated due to incomplete registry data for patients receiving dialysis following acute decompensation (25) ( Fig. 1 ). In the United Kingdom, 19% of deaths within 1 year of commencing dialysis among patients aged over 65 are due to withdrawal from treatment and rates are rising (4) .
For much of the globe, there remains a deficiency of organized data on the incidence and prevalence of ESKF, provision for its treatment and its outcomes (26) . Considerable portions of the world population have no access to specialist renal services. Once ESKF develops individuals are likely to either remain undiagnosed, or be diagnosed and unable to access RRT. Reported global incidence rates for RRT-treated ESKF range from 12 to 455 (median 130) per million population (3). This variation reflects factors including population health and demography including disease burden. However, macroeconomic and service factors such as Gross Domestic Product spent per capita, percentage of Gross Domestic Product spent on health care, dialysis reimbursement rate and the private for profit share of dialysis provision are more strongly associated (3) . Work needs to be done to join up these various sources of data on CKD in different settings and gain a full picture of the care of people with CKD and ESKF, though the solutions are likely to have to be specific to the databases and information governance laws in the different countries.
Provision of Nondialysis Care
While CCC is recognized and delivered widely (19, 20, (27) (28) (29) , the international population of individuals receiving CCC has not been evaluated. Scope and practice patterns of CCC in the United Kingdom have been systematically recorded (20) . A nondialysis pathway was available in nearly every UK renal unit. Data on the number of older patients on a nondialysis pathway were available for almost half of units, and varied greatly from 4 to 152, often but not always reflecting the total population of patients in a unit. Data on symptomatic older patients on a nondialysis pathway, perhaps a better gauge of CCC delivery, also varied widely, ranging from 1 to 50 patients per unit. Approximately one in five units had clinics exclusively for patients on a nondialysis pathway and this was closely related to whether they had staff primarily responsible, and funding, for nondialysis care. Unlike RRT preparation and delivery, CCC receives no automatic payment by results within UK healthcare tariffs. Linkage with primary care data was available for a small number of units and suggested that most (94%) individuals with CKD stage 5 were known to renal services. What degree of triage occurred before laboratory testing in primary care was not examined.
The very wide variation in numbers of patients receiving nondialysis care (20) is likely to reflect, in part, the lack of an agreed definition of the pathway and highlights the need for a uniform terminology (19) . Variation also reflects local CKD identification, referral and treatment patterns along with deviation in population demographics. The trend over the past decade has been for increasing investment in such services (30) and some units have shown considerable investment in staff time and dedicated processes to support patients on a nondialysis pathway.
In 2013, Kidney Disease: Improving Global Outcomes (KDIGO), in partnership with the International Society of Nephrology (ISN), held a conference to develop consensus on the application of palliative care in CKD (18) . The lack of clear definitions was felt to have constrained both treatment and research for this population. A definition of CCC was proposed including all aspects of care for individuals with ESKF managed without RRT ( Table 1 ). The conference represented a milestone in the care of patients with or approaching ESKF and prepared the ground for development of an evidence base from which care and outcomes can be improved.
Treatment of Individuals with or Approaching ESKF: A Proposed Terminology
An agreed terminology for treatment of those with or approaching ESKF is necessary to facilitate communication with patients, carers, clinicians and policy makers. In research and policy, evidence, guidance and direction can be developed only once patient populations are defined. The KDIGO/ISN conference defined supportive care and CCC, but did not produce a classification of treatment pathways where both RRT and CCC are available (18) . A classification is proposed in Fig. 2 .
The proposed classification uses 'ESKF' to describe sufficiently impaired kidney function such that individuals are in receipt of either RRT or CCC (after a putative point similar to an indication to start RRT). Estimated glomerular filtration rate (eGFR) associates imperfectly with disease severity and cannot alone identify ESKF (31) . Serum creatinine reflects body composition as well as renal function and loses precision as a marker of kidney function in individuals with low muscle mass, malnourishment, or at extremes of age (32) . Some individuals with an eGFR as high as ≥15 ml/minute/ 1.73 m 2 have substantial symptoms or biochemical complications and a small number initiate dialysis at this stage (33) . Many patients with eGFR < 15 ml/minute/1.73 m 2 have acceptable fluid balance, biochemistry and symptom control and stability of kidney function.
Initiation of dialysis is not an unambiguous marker of ESKF. Initiating dialysis preemptively does not provide benefit over waiting for an indication to commence treatment (34) . Symptoms, hyperkalemia and fluid overload increase with declining kidney function, but are not categorical phenomena-the risk of sudden death, for example, increases progressively with rising serum potassium concentration (35) . Individuals (36) and their clinicians (37) weigh potential benefits and burdens of treatment differently depending on personal preferences and values and despite similar disease profiles, may initiate dialysis-thus acquiring a label of treated ESKFat different times. Some will consider the benefits of dialysis insufficient to outweigh the burdens and choose nondialysis care (36) . The point at which such individuals have progressed from nondialysis preparation to CCC may be difficult to identify with precision. The proposed classification recognizes the difference between individuals who are not planning for RRT if ESKF develops and others receiving CCC who would be undergoing dialysis if that had been the chosen mode of care. However, the dividing lines are indistinct, reflecting gradual progression of disease, plasticity of decision-making and the elusiveness of a definition for ESKF.
Decision-making is a process, not an epiphany and this is reflected by the ability for patients to move freely between the pathways, both at preparatory and ESKF phases. Individuals presenting late to renal services ( Fig. 1 ) may develop ESKF without being on either pathway and need to elect for RRT or CCC at short notice.
Access to supportive care, advance planning and palliative services should not be influenced by which pathway a patient has chosen. As comorbidities develop and an end of life phase approaches, care may become progressively palliative on either pathway and some patients receiving RRT may choose to withdraw from dialysis. A greater proportion of patients opting for CCC may already be at this stage, but supportive care is a component of both pathways as depicted in Fig. 2 .
Comparing Outcomes between RRT and
Nondialysis Care Tables 2 and 3 summarize key studies that have compared the outcomes of patients receiving nondialysis and RRT care. All have been observational in design, and with only three prospective cohorts (29, 38, 39) . Most have been single center and from the United Kingdom, including three from the same unit (38, 40, 41) . The cohorts are small, with only four including over 100 patients on a nondialysis pathway. In total, 913 patients receiving nondialysis care were included. There are methodological issues with the comparisons which include: dealing with selection bias in allocation (treatment by indication) and residual confounding; identification of a start time for survival analysis with long lead times in advanced CKD (and potential for lead time bias); exclusion criteria; uncertain disease progression and prognosis in individuals approaching ESKF; and variation in threshold for RRT initiation between individuals, units and countries; cross-over between pathways and failure of intention to treat analysis, and limited outcome data.
Patients on a nondialysis pathway tended to be older, more comorbid and have poorer functional status (38, (41) (42) (43) , although this was not found in all studies (39) . Selection bias was addressed by restriction or multivariate analysis including propensity scoring (see Table 3 ). However, residual confounding was a problem given the limited set of routinely available variables in retrospective studies from which adjustments can be made. There was typically no adjustment made for functional status, frailty, malnutrition, or cognitive impairment.
Identifying equivalent time points for individuals on RRT and nondialysis pathways is necessary for survival comparisons. Approaches to start time allocation have included time of recording of decisionmaking (intention to treat), estimating a putative eGFR indicating ESKF and its timing in those on a nondialysis pathway, and time of reaching a threshold eGFR (see Table 2 ). Time of decision-making fails to distinguish patients in a preparatory phase from those in receipt of CCC and treatment decisions may be made at different times among those who choose RRT and nondialysis pathways. Most studies excluded individuals first presenting to renal services with an eGFR <10-15 mls/minute on the grounds there was little time for decisionmaking and high use of RRT in this group. Such patients are often older and more comorbid and are likely to have poor outcomes. The limitations of eGFR as a marker of ESKF have already been outlined. Outcome data available were largely restricted to survival, with a lack of cause of death statistics to inform the role of direct death from ESKF in those treated with CCC. Only three studies investigated quality of life (29, 38, 39) .
Compared with patients of the same age receiving dialysis, there was a survival disadvantage associated with nondialysis care, but this diminished and even disappeared when comparison was restricted to patients with high comorbidity or on multivariate analysis (40, (43) (44) (45) (46) , though this was not found in all studies (38, 47) . Patients receiving nondialysis care were more likely to die out of hospital, with palliative care input, and less likely to have an 'over-medicalised' death (41, 43, 45, 48) . The patients receiving RRT, who were largely treated with in-center hemodialysis, had greater (43, 47, 48) , except in one study of patients receiving peritoneal dialysis, where the reverse was found (45) . In the three studies that examined changes in quality of life (29, 38, 39) , there were some baseline differences with lower scores in patients on a nondialysis pathway, notably in terms of their physical health. However, quality of life was more stable over time in those receiving nondialysis care in contrast to those who started dialysis, where an adverse impact on burden of disease and life satisfaction was seen, with no apparent quality of life gained. 
Attitudes of Medical Staff, Patients, and their Families to CCC
Given the lack of high-quality comparative outcome data to guide decision-making, it is crucial to understand how clinicians and patients view management options. Different patients may view the same treatment in different ways and it is important for clinicians to understand individual patients' needs and how these may influence decisions. Qualitative research, aimed at exploring people's views of various life experiences, can help to unearth the beliefs and expectations people hold regarding their health, quality of life, and medical treatments.
A significant proportion of the qualitative literature has explored patients' perceptions of choosing between types of ESKF treatment, most frequently between dialysis modalities, and living with dialysis. Qualitative syntheses of this type of work have highlighted that patients consider various aspects when deciding what type of treatment is right for them (49, 50) . Patients are seen to consider the effect of treatment on their lifestyle and the impact on family members. They can experience great uncertainty when making treatment choices as they are unclear how their CKD is likely to progress and unsure about what different treatment approaches can offer.
More recently, researchers have started to explore patients' views of nondialysis care. Five studies have explored older patients' reasons for choosing nondialysis care (28, 36, (51) (52) (53) . These indicate that the perceived burden of dialysis is a common reason why patients may choose nondialysis care. Patients report that their age and functional ability make attending dialysis sessions demanding and, as a consequence, feel dialysis would negatively affect their quality of life (51) (52) (53) . Many older adults report difficulties in attending dialysis either because of availability of transport, time taken, or cost of travel (51) . Patients also feel that choosing dialysis may be a burden on family members; interrupting their lives or causing them emotional stress (28) . Such practicalities can outweigh perceived benefit of dialysis and those who feel they have lived a fulfilled life may not want treatment that disrupts their way of living (28, 36, 53) .
When choosing nondialysis care patients most often report feeling that they have made an informed and autonomous decision (28, 36) . Patients report having opportunities to discuss their options with clinical staff and feel equipped to make decisions (52) . However, patients state that information about dialysis is often given priority by staff and that nondialysis care may be discussed little or not at all (53) . Decision aids and information leaflets are likely to be heavily weighted toward dialysis options, possibly reflecting the amount of evidence in this area.
Interviews with individuals indicate that patients may hold misunderstandings about CKD as a disease and what treatment can offer. Most often patients are uncertain about how their disease will progress and what this will mean for the future. Some patients opting for nondialysis care report feeling well, reporting no symptoms from their CKD and as a result do not see the need for dialysis (52, 53) . Patients can fail to recognize how their CKD may progress and make treatment decisions based on how they feel in the present rather than on how they might feel in the future (51) . This could explain why some patients change their minds and request dialysis once symptoms develop (53) .
A small number of studies have explored clinicians' views on how treatment decisions are made with patients (20, 54, 55) . Interviews with health professionals have highlighted the difficulty nephrology staff have in explaining CKD treatment and getting patients to appreciate the severity of the disease (20, 54, 55) . Lack of public awareness of CKD and its treatment are perceived to contribute to this. Clinicians report additional challenges such as tailoring information to the educational level of the patient, eliciting patient concerns about treatment options and discussing options with patients who fear dialysis after hearing the experiences of others (54) . Clinicians often report the importance of timing discussions so patients not only have enough time to understand the information, but also introducing new material to patients gradually to avoid anxiety (55) .
Clinicians report that uncertainty about disease progression makes it hard to advise patients on management options and to prepare them for future treatment (20, 55) . Uncertainty can lead to clinicians avoiding discussions about the future; fearing that information will be too negative for patients (55) . Discussions about prognosis or end of life may be delayed until prompted by the patient or by illness progression.
Only one study to date has specifically sought clinicians' views on nondialysis care (20) . Clinicians generally accepted it as an alternative to dialysis, with most being grateful that they could offer something to patients if they did not choose dialysis. Clinicians reported that discussing nondialysis options with patients was a difficult task, more suited to experienced professionals because of the complexity and sensitivity of end of life issues. Clinicians felt more able to have these discussions when they felt confident in talking about end of life and in eliciting patient expectations. Such open discussions were felt to prevent misunderstandings and patients changing their mind between treatment options when symptoms developed at a later stage (20) . Similar qualitative work with clinicians focusing on advanced care planning for patients with CKD has also identified that staff may not view such discussions as part of their role and that clinical teams may not have a shared understanding of advanced care planning (56). Research with patients indicates that timely information regarding ACP can help to support patient's psychological needs when undergoing treatment for ESKF (57) . 
Components of Nondialysis Care
Patients who choose the nondialysis pathway are generally pursuing a less disruptive approach to their care (49) . Balancing minimal therapeutic burden with maximal symptom control requires an enhanced focus on individualized goals, preferences, and values. Ascertainment of these must be a routine component of planning treatment. Clinicians who can elicit expectations can correct misconceptions and help individuals understand how treatment options might impact upon their quality and quantity of life. Practicalities of treatment need to be considered alongside clinical benefits in order for patients to frame decisions in relation to their own lives. The organization of available nondialysis care is varied (19, 20, 56) and there is no evidence available to identify best practice. Systems that encourage continuity of care and guidance from multidisciplinary teams trained and experienced in communication skills, shared decision-making, end of life discussions, and advance care planning may be best. Integration with primary and palliative care services is needed.
The components of CCC are summarized in Table 1 (18) . However, all individuals with advanced CKD need these components addressed and ultimately it is preparation for and delivery of RRT which delineates the care pathways. Given the evolving nature of disease and personal preferences, regular review is needed to ensure treatment is aligned with achievable goals. For some, this will involve movement between the care pathways ( Fig. 2) . Many individuals will wish to concentrate on quality of life over longevity. Others may value life extension more highly and this stance is not discordant with nondialysis care for those with a poor prognosis. Potential therapeutic benefits are offset by treatment burdens, side effects, and the competing risk of death.
The majority of patients in a nondialysis preparation phase will receive treatment undifferentiated from routine CKD care. Those approaching end of life and those who develop ESKF may choose to reduce or stop treatment such as antihypertensives that offer no immediate symptomatic benefit and a low probability of life prolongation. Others will decide to continue such treatment if they feel the benefits outweigh the burdens. High quality shared decision-making is needed to facilitate informed choices. Treatment for patients on the nondialysis pathway is summarized in Table 4 .
The Future of Nondialysis Care-Conclusion and Recommendations
Given the human and economic impact of dialysis, there is a pressing need to establish the comparative effectiveness and cost-effectiveness of RRT and nondialysis care. It is incumbent on the nephrology community to generate the best possible evidence of person-centered health outcomes associated with each treatment approach and learn how to present this evidence to patients in a way that allows them to make decisions that are most appropriate for them. The following five recommendations are focussed on this aim.
1. Agreed definitions are required that clearly distinguish phases of treatment. A suggested framework is proposed (Fig. 2) . 2. Nondialysis care should be discussed early and openly with patients approaching ESKF and should feature more prominently in decisionsupport materials. 3. Improved observational and organizational research is needed to gain a better understanding of the natural history of advanced CKD and ESKF and to identify the most effective and efficient ways to deliver care and monitor equity of care. This could be achieved through a combination of extending RRT registries to capture earlier stages of CKD and by studying routine hospital and primary care databases. Improved capture of early dialysis outcomes and inclusion of patients with CKD including those on CCC (58) will improve data capture in areas known to be deficient ( Fig. 1) . Auditable standards and quality assurance data could help to coordinate more consistent care at a national level, and ensure equity of delivery. 4. The viability of a trial comparing the effectiveness and cost-effectiveness of nondialysis and RRT care pathways in individuals where clinical equipoise exists should be investigated. While practical and ethical intricacies make this challenging, observational data may never be able to separate unmeasured confounding by indication from treatment effect. 5. Working with colleagues in primary care and palliative medicine, the renal community must continue to strive to improve dialysis outcomes for older patients and those with multiple comorbidities, including greater use of home and assisted therapies. The benefits and risks of RRT are not fixed and whatever evidence is generated regarding nondialysis pathways will need to keep pace with advances in practice.
